Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

NCT01136967 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01136967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01136967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
November 30, 2014
Enrollment
182 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv melanoma, unresectable stage iii